Table 5.

Characteristics of secukinumab use among patients with PsA (N = 153)

Characteristic	Patients with PsA (N = 153)
Duration of treatment with secukinumab, mean (SD), monthsa	5.9 (4.6)
Dose
Received loading regimen, n (%)	144 (94.1)
150 mg every weekb	50 (32.7)
300 mg every weekc	94 (61.4)
No loading regimen	9 (5.9)
Received maintenance dose, n (%)	145 (94.8)
Initial maintenance dosed
150 mg every 4 weeks	72 (49.7)
300 mg every 4 weeks	73 (50.3)
Current secukinumab use, n (%)
Still receiving secukinumab	138 (90.2)
Discontinued secukinumab	9 (5.9)
Reason for secukinumab discontinuation, n (%)e
Lack/loss of efficacy/effectiveness	5 (55.6)
Intolerance to the treatment	2 (22.2)
Adverse events from the treatment	2 (22.2)
Worsening or new comorbid condition	1 (11.1)
Unknown secukinumab treatment status	6 (3.9)

PsA psoriatic arthritis; SD standard deviation

^aDuration of treatment with secukinumab was calculated among all patients; the calculated duration may underestimate the true duration because most patients were still receiving secukinumab at the time of chart abstraction

^bAmong the 50 patients who initiated secukinumab at 150 mg every week, 43 received an initial maintenance dose of 150 mg every 4 weeks, 6 received 300 mg every 4 weeks, and 1 did not receive maintenance treatment

^cAmong the 94 patients who initiated secukinumab at 300 mg every week, 25 received an initial maintenance dose of 150 mg every 4 weeks, 63 received 300 mg every 4 weeks, 2 did not receive maintenance treatment, and 4 did not remain on the therapy long enough to receive maintenance treatment

^dThe proportions of initial maintenance doses were calculated among patients who received a maintenance dose

^eThe proportions of reasons for discontinuation were calculated among patients who discontinued secukinumab. Multiple reasons could be selected for each patient